Drug profile · INN
alemtuzumab
LEMTRADA
alemtuzumab (LEMTRADA) is a campath-1 antigen inhibitor. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — alemtuzumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
alemtuzumab (LEMTRADA) is a campath-1 antigen inhibitor. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
CAMPATH-1 antigen inhibitor
Primary target: CAMPATH-1 antigen
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is alemtuzumab?
alemtuzumab (LEMTRADA) is a campath-1 antigen inhibitor. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for alemtuzumab?
LEMTRADA is a marketed brand name for alemtuzumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of alemtuzumab?
alemtuzumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.